Proteomic strategies in bladder cancer: From tissue to fluid and back

Gromov, Pavel; Moreira, José M.A.; Gromova, Irina; Celis, Julio E.

doi:10.1002/prca.200780163

Cited by 11 publications

(8 citation statements)

References 140 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tests include the bladder tumor antigen (BTA) (10), nuclear matrix protein 22 (NMP-22) (11, 12), BLCA-4, cytokeratin (13), psoriasin (S100A7) (14), fibronectin (FG)/degradation products (FDPs) (15, 16), zinc-alpha2-glycoprotein (17). However, these markers have limited sensitivity, so alone they are not yet sufficient to replace the gold standards of urine cytology or cystoscopy (18, 19).…”

Section: Introductionmentioning

confidence: 99%

Urinary Glycoprotein Biomarker Discovery for Bladder Cancer Detection Using LC/MS-MS and Label-Free Quantification

Yang

Feng

Shedden

et al. 2011

Clinical Cancer Research

130

118

View full text Add to dashboard Cite

Background Cancers of the urinary bladder are the fifth most commonly diagnosed malignancy in the US. Early clinical diagnosis of bladder cancer remains a major challenge and the development of non-invasive methods for detection and surveillance is desirable for both patients and health care providers. Approach In order to identify urinary proteins with potential clinical utility we enriched and profiled the glycoprotein component of urine samples using a dual-lectin affinity chromatography and LC-MS/MS platform. Results From a primary sample set obtained from 54 cancer patients and 46 controls a total of 265 distinct glycoproteins were identified with high confidence, and changes in glycoprotein abundance between groups were quantified by a label-free spectral counting method. Validation of candidate biomarker alpha-1-antitrypsin (A1AT) for disease association was performed on an independent set of 70 samples (35 cancer cases) using an ELISA. Increased levels of urinary alpha-1-antitrypsin (A1AT) glycoprotein were indicative of the presence of bladder cancer (p value < 0.0001) and augmented voided urine cytology results. A1AT detection classified bladder cancer patients with a sensitivity of 74% and specificity of 80%. Summary The described strategy can enable higher resolution profiling of the proteome in biological fluids by reducing complexity. Application of glycoprotein enrichment provided novel candidates for further investigation as biomarkers for the non-invasive detection of bladder cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Urinary Glycoprotein Biomarker Discovery for Bladder Cancer Detection Using LC/MS-MS and Label-Free Quantification

Yang

Feng

Shedden

et al. 2011

Clinical Cancer Research

130

118

View full text Add to dashboard Cite

show abstract

“…This protein-rich fluid is neither as variable or diluted as urine, nor as complex as serum. Therefore, it represents a new and interesting fluid for biomarker discovery [33].…”

Section: Reviewmentioning

confidence: 99%

Tissue and serum proteomic profiling for diagnostic and prognostic bladder cancer biomarkers

Schwamborn

Gaisa

Henkel

2010

Expert Review of Proteomics

View full text Add to dashboard Cite

A panel of biomarkers for the early detection of bladder cancer has not yet been identified. Many different molecules, including DNA, RNA or proteins have been reported but none have provided adequate sensitivity for a single-tier screening test or a test to replace cystoscopy. Therefore, multimarker panels are discussed at present to give a more-precise answer to the biomarker quest. Mass spectrometry or 2D gel-electrophoresis have evolved greatly within recent years and are capable of analyzing multiple proteins or peptides in parallel with high sensitivity and specificity. However, transmission of screening results from one laboratory to another is still the main pitfall of those methods; a fact that emphasizes the need for consistent and standardized procedures as suggested by the Human Proteome Organization (HUPO). In this article, recent results in screening approaches and other proteomic techniques used for biomarker evaluation in bladder cancer are discussed with a focus on serum and tissue biomarkers.

show abstract

“…Although nucleic acid‐based diagnostic technologies have been introduced for clinical practice, historically protein‐based tests have been used for clinical examinations, because proteins reflect the dynamic change in association with disease status in contrast to genes. The protein‐based tests using biological body fluids have the advantage because body fluids might not contain nucleic acids . In addition, proteomics can resolve some problems, such as post‐translational modifications, intracellular localization, protein turnover, protein–protein interactions and so on, which cannot be addressed by genomics.…”

Section: Introductionmentioning

confidence: 99%

Proteome research in urothelial carcinoma

et al. 2015

View full text Add to dashboard Cite

Abbreviations & Acronyms 2D-DIGE = two-dimensional difference gel electrophoresis 2DE = two-dimensional electrophoresis A-FABP = adipocyte-fatty acid binding protein Apo-A1 = apolipoprotein A1 EGFR = epidermal growth factor receptor ELISA = enzyme-linked immunosorbent assay ESI = electrospray ionization GGCT = gammaglutamylcyclotransferase iTRAQ = isobaric tags for relative and absolute quantification LC = liquid chromatography MALDI = matrix-assisted laser desorption/ionization MS = mass spectrometry MS/MS = tandem mass spectrometry m/z = mass-to-charge ratio SELDI = surface-enhanced laser desorption/ionization SILAC = stable isotope labeling by amino acid in cell culture Abstract: In all creatures including humans, the molecules that function in accordance with the genetic code are mainly proteins. After completing the sequencing of the human genome, rapid progress has been made in proteome analysis. The primary structures of almost all proteins were determined by the human genome sequence. However, the whole picture of proteins cannot be elucidated because of alternative splicing and posttranslational modifications. Therefore, genomic as well as systematic and comprehensive information of proteins is required. Modern methods of proteomics have dramatically improved the quality and speed of protein analysis. Developments in both bioinformatics and mass spectrometry have contributed to the technical improvement, making it possible to identify proteins in a short time with high accuracy even from a very small sample. In the field of cancer research, many studies of useful diagnostic and prognostic biomarkers using these proteomic technologies have been reported, and target molecules for treatment have been explored. The aim of the present review was to summarize the basic technologies of proteomics and recent research in the field of urothelial cancer obtained using proteomic methods.

show abstract

Proteomic strategies in bladder cancer: From tissue to fluid and back

Cited by 11 publications

References 140 publications

Urinary Glycoprotein Biomarker Discovery for Bladder Cancer Detection Using LC/MS-MS and Label-Free Quantification

Urinary Glycoprotein Biomarker Discovery for Bladder Cancer Detection Using LC/MS-MS and Label-Free Quantification

Tissue and serum proteomic profiling for diagnostic and prognostic bladder cancer biomarkers

Proteome research in urothelial carcinoma

Contact Info

Product

Resources

About